Odabaşı Güneş Sevinç, Peltek Kendirci Havva Nur, Ünal Edip, Buluş Ayşe Derya, Dündar İsmail, Şıklar Zeynep
University of Health Sciences Turkey, Gülhane Training and Research Hospital, Clinic of Pediatric Endocrinology, Ankara, Turkey
Hitit University Faculty of Medicine, Department of Pediatric Endocrinology, Çorum, Turkey
J Clin Res Pediatr Endocrinol. 2025 Jan 10;17(Suppl 1):3-11. doi: 10.4274/jcrpe.galenos.2024.2024-6-6-S. Epub 2024 Dec 23.
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disease caused by the deficiency of one of the enzymes involved in cortisol synthesis. Between 90% and 99% of cases of CAH are caused by 21-hydroxylase deficiency (21-OHD) caused by mutations in . Although 21-OHD has been historically divided into classical and non-classical forms, it is now thought to show a continuous phenotype. In the classical form, the external genitalia in females becomes virilized to varying degrees. If the disease is not recognized, salt wasting crises in the classical form may threaten life in neonates. Children experience accelerated somatic growth, increased bone age, and premature pubic hair in the simple virilizing form of classical 21-OHD. Female adolescents may present with severe acne, hirsutism, androgenic alopecia, menstrual irregularity or primary amenorrhea in the non-classical form. Diagnosis of CAH is made by clinical, biochemical and molecular genetic evaluation. In cases of 21-OHD, the diagnosis is based on the 17-hydroxyprogesterone (17-OHP) level being above 1000 ng/dL, measured early in the morning. In cases with borderline 17-OHP levels (200-1000 ng/dL), it is recommended to perform an adrenocorticotropic hormone (ACTH) stimulation test. Genotyping in cases with CAH should be performed if the adrenocortical profile is suspicious or if the ACTH stimulation test cannot be performed completely. After diagnosis, determining the carrier status of the parents and determining which parent the mutation was passed on from will help in interpreting the genetic results and determining the risk of recurrence in subsequent pregnancies.
先天性肾上腺皮质增生症(CAH)是一种常染色体隐性疾病,由参与皮质醇合成的一种酶缺乏引起。90%至99%的CAH病例是由 基因 突变导致的21-羟化酶缺乏症(21-OHD)引起的。尽管21-OHD在历史上被分为经典型和非经典型,但现在认为它表现出连续的表型。在经典型中,女性的外生殖器会出现不同程度的男性化。如果疾病未被识别,经典型中的失盐危象可能会威胁新生儿的生命。在经典21-OHD的单纯男性化型中,儿童会经历加速的身体生长、骨龄增加和阴毛早熟。非经典型的女性青少年可能会出现严重痤疮、多毛症、雄激素性脱发、月经不规律或原发性闭经。CAH的诊断通过临床、生化和分子遗传学评估来进行。在21-OHD病例中,诊断基于清晨测得的17-羟孕酮(17-OHP)水平高于1000 ng/dL。在17-OHP水平处于临界值(200 - 1000 ng/dL)的病例中,建议进行促肾上腺皮质激素(ACTH)刺激试验。如果肾上腺皮质检查结果可疑或无法完全进行ACTH刺激试验,则应对CAH病例进行基因分型。诊断后,确定父母的携带者状态以及确定突变是从哪一方父母遗传而来,将有助于解释基因检测结果并确定后续妊娠的复发风险。